AI News

Harvey raised $200M last year. They built their legal AI product on top of Claude, Anthropic's model. A few weeks ago, Anthropic launched Claude for Legal, their own product aimed directly at the same market.

Anthropic has begun developing tools that directly compete with companies building on top of their models. Harvey's bet was that their product layer would be defensible. The workflows, the trust, the enterprise contracts. That bet just got harder.

Isomorphic Labs just closed a $2.1 billion Series B. They're using AI to design drug molecules from scratch, not to accelerate existing research methods but to generate candidates that human scientists wouldn't have known to look for.

They're based in London. The AlphaFold research that underpins all of this came out of DeepMind, also London. This isn't just a funding story. The talent doing the most serious AI research in biomedicine isn't concentrated in one zip code in California. That window is open in a lot of places right now.